Complement, cold agglutinins, and therapy

Blood

Volumn 123, Issue 26, 2014, Pages 4010-4012

  Berentsen, Sigbjørn ^a  

^a HAUGESUND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; COLD AGGLUTININ; COMPLEMENT; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; FLUDARABINE; HEMOGLOBIN; MONOCLONAL ANTIBODY; RITUXIMAB;

ACUTE PHASE RESPONSE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; CELL DESTRUCTION; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; ERYTHROPHAGOCYTOSIS; HEMAGGLUTINATION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HEMOLYSIS; HUMAN; IN VITRO STUDY; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; NOTE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHAGOCYTE; PRIMARY CHRONIC COLD AGGLUTIN DISEASE; PRIORITY JOURNAL;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COMPLEMENT ACTIVATION; COMPLEMENT C1S; FEMALE; HUMANS; MALE; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS;

EID: 84903589784     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-568733     Document Type: Note

References (10)

1. Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123(26):4015-4022.
2. Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497-504.
3. Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest. 1976;58(4):942-949.
4. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460-466.
5. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121.
6. Ulvestad E, Berentsen S, Mollnes TE. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol. 2001;54(1-2):239-242. (Pubitemid 32592351)
7. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925-2928. (Pubitemid 38451661)
8. Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116(17):3180-3184.
9. Röth A, Hüttmann A, Rother RP, Dührsen U, Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood. 2009;113(16):3885-3886.
10. Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123(13):2094-2101.